Data from FDA (Food and Drug Administration, USA) - Curated by EPG Health - Last updated 07 May 2018

Indication(s)

Kogenate FS is an Antihemophilic Factor (Recombinant) indicated for:
• Control and prevention of bleeding episodes in adults and children with hemophilia A.
• Peri-operative management in adults and children with hemophilia A.
• Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in children with hemophilia A and to reduce the risk of joint damage in children without pre-existing joint damage.
• Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A.

Kogenate FS is not indicated for the treatment of von Willebrand disease.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Oral Anticoagulation Reversal

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Cystic Fibrosis

Cystic Fibrosis

View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.

+ 1 more

Load more

Related Content

Advisory information

contraindications
Do not use in patients who have life-threatening hypersensitivity reactions, including anaphylaxis to mouse or hamster protein or other constituents of the product (4).
Special warnings and precautions
• Hypersensitivity reactions, including anaphylaxis, are possible. Should symptoms occur, discontinue treatment with Kogenate FS and administer appropriate treatment (5.1).
• Development of activity-neutralizing antibodies can occur in patients receiving factor VIII-containing products, including Kogenate FS. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an expected dose, perform an assay that measures factor VIII inhibitor concentration (5.2).
• Monitor plasma factor VIII levels during infusions when indicated (5.3).
• When clotting is normalized by treatment with factor VIII, development of cardiovascular risk factors may be the same as the risk for nonhemophilic patients (5.4).
Adverse reactions

The most common adverse reactions (≥4%) in clinical trials are inhibitor formation (neutralizing antibodies) in previously untreated and minimally treated patients (PUPs and MTPs), skin-associated hypersensitivity reactions (e.g., rash, pruritus, urticaria), infusion site reactions (e.g., inflammation, pain), and central venous access device (CVAD) associated infections.

Usage information

Dosing and administration
For intravenous use only.
• Each vial of Kogenate FS contains the labeled amount of recombinant factor VIII in international units (IU, unit).

Control and prevention of bleeding episodes and peri-operative management (2.1):
• Dose (units) = body weight (kg) x desired factor VIII rise (IU/dL or % of normal) x 0.5 (IU/kg per IU/dL).
• Titrate doses to patient’s clinical response.
• Determine treatment frequency based on type of bleeding episode.

For routine prophylaxis in adults: 25 units per kg three times a week (2.1).

For routine prophylaxis in children: 25 units per kg every other day (2.1).
Use in special populations
• Pregnancy: No human or animal data. Use only if clearly needed (8.1).
• Pediatric Use: Higher factor VIII clearance may occur in children (4.4– 16 years). Dose adjustment may be needed (8.4).

More information

Category Value
Authorisation number BLA103332
Orphan designation No
Product NDC 0026-3782; 0026-3783; 0026-3785; 0026-3786; 0026-3787; 0026-3792; 0026-3793; 0026-3795; 0026-3796; 0026-3797
Date First Approved 26-06-2000
Marketing authorisation holder Bayer HealthCare LLC